Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nexalin Technology, Inc. - Warrant
(NQ:
NXLIW
)
0.2502
-0.0499 (-16.63%)
Streaming Delayed Price
Updated: 10:50 AM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nexalin Technology, Inc. - Warrant
< Previous
1
2
Next >
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
October 16, 2023
Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and...
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
August 07, 2023
New migraine data builds on prior clinical studies in depression
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
August 03, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
July 26, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10, 2023
New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
June 01, 2023
Wider Come to fund and conduct a total of four clinical trials, spanning insomnia, depression and other indications
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
January 24, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders
January 05, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
November 14, 2022
From
Nexalin Technology, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.